Copyright
©The Author(s) 2022.
World J Cardiol. Nov 26, 2022; 14(11): 599-616
Published online Nov 26, 2022. doi: 10.4330/wjc.v14.i11.599
Published online Nov 26, 2022. doi: 10.4330/wjc.v14.i11.599
Table 4 Baseline data for HbA1C, BW, and UA
| Body weight (kg) | Hemoglobin A1c (%) | Uric acid (mg/dL) | |||||
| Ref. | SGLT2-I (daily dose, mg) | SGLT2-I | Placebo | SGLT2-I | Placebo | SGLT2-I | Placebo |
| Bailey et al[25], 2013 | DAPA (2.5) | 84.90 (17.77) | 87.74 (19.24) | 7.99 (0.90) | 8.12 (0.96) | ||
| DAPA (5) | 84.73 (16.26) | 8.17 (0.96) | |||||
| DAPA (10) | 86.28 (17.53) | 7.92 (0.82) | |||||
| Bailey et al[24], 2015 | DAPA (2.5) | 90.8 (22.8) | 88.8 (19.0) | 7.92 (0.90) | 7.84 (0.87) | 5.92 (1.42) | 5.09 (1.32) |
| DAPA (5) | 87.6 (17.1) | 7.86 (0.94) | 5.55 (1.44) | ||||
| DAPA (10) | 94.2 (18.7) | 8.01 (0.96) | 5.67 (1.44) | ||||
| Bolinder et al[33], 2014 | DAPA (10) | 92.1 (14.1) | 90.9 (13.7) | 7.19 (0.44) | 7.16 (0.53) | ||
| Brown et al[35], 2020 | DAPA (10) | 91.58 (14.62) | 91.48 (14.13) | 7.8 (3.17) | 7.66 (3.08) | ||
| Jabbour et al[30], 2014 | DAPA (10) | 91.0 (21.6) | 89.2 (20.9) | 7.9 (0.8) | 8.0 (0.8) | ||
| Kohan et al[28], 2016 | DAPA (2.5) | 8.17 (0.86) | 8.12 (0.92) | ||||
| DAPA (5) | 8.27 (0.95) | ||||||
| DAPA (10) | 8.11 (0.93) | ||||||
| List et al[39], 2009 | DAPA (2.5) | 90 (20) | 89 (18) | 7.6 (0.7) | 7.9 (0.9) | 5.5 (1.2) | 5.5 (1.4) |
| DAPA (5) | 89 (17) | 8.0 (0.9) | 5.2 (1.3) | ||||
| DAPA (10) | 86 (17) | 8.0 (0.8) | 5.5 (1.2) | ||||
| DAPA (20) | 88 (18) | 7.7 (0.9) | 5.3 (1.3) | ||||
| DAPA (50) | 92 (19) | 7.8 (1.0) | 5.6 (1.4) | ||||
| Matthaei et al[34], 2015 | DAPA (10) | 88.6 (17.6) | 90.1 (16.2) | 8.08 (0.91) | 8.24 (0.87) | ||
| Rosenstock et al[26], 2012 | DAPA (5) | 87.8 (20.7) | 86.4 (21.3) | 8.40 (1.03) | 8.34 (1.00) | ||
| DAPA (10) | 84.8 (22.2) | 8.37 (0.96) | |||||
| Wilding et al[27], 2014 | DAPA (2.5) | 93.0 (16.7) | 94.5 (19.8) | 8.46 (0.78) | 8.47 (0.77) | ||
| DAPA (5/10)1 | 93.3 (17.4) | 8.62 (0.89) | |||||
| DAPA (10) | 94.5 (16.8) | 8.57 (0.82) | |||||
| Anker et al[15], 2021 | EMPA (10) | ||||||
| Sone et al[36], 2020 | EMPA (10) | 73.3 (11.5) | 74.0 (11.3) | 8.8 (0.7) | 8.7 (0.7) | ||
| EMPA (25) | 72.2 (11.4) | 8.7 (0.7) | |||||
| Rosenstock et al[37], 2015 | EMPA (10) | 91.6 (20.1) | 90.5 (22.5) | 8.3 (0.8) | 8.2 (0.8) | 5.26 (1.71) | 5.5 (2.1) |
| EMPA (25) | 94.7 (20.7) | 8.3 (0.8) | 5.63 (2) | ||||
| Rosenstock et al[38], 2014 | EMPA (10) | 96.7 (17.9) | 95.5 (17.5) | 8.39 (0.74) | 8.33 (0.72) | 5.48 (2.13) | 5.5 (2.0) |
| EMPA (25) | 95.9 (17.3) | 8.29 (0.72) | 5.56 (2.07) | ||||
| Zinman et al[5], 2015 | EMPA (10) | 85.9 (18.8) | 86.6 (19.1) | 8.07 (0.86) | 8.08 (0.84) | 5.9 | 6 |
| EMPA (25) | 86.5 (19.0) | 8.06 (0.84) | 5.98 | ||||
- Citation: Olagunju A, Yamani N, Kenny D, Mookadam M, Mookadam F, Unzek S. Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. World J Cardiol 2022; 14(11): 599-616
- URL: https://www.wjgnet.com/1949-8462/full/v14/i11/599.htm
- DOI: https://dx.doi.org/10.4330/wjc.v14.i11.599